INDV Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Indivior PLC for Potential Securities Law ViolationsGlobeNewsWire • 07/09/24
What's Going On With Addiction And Mental Illnesses-Focused Indivior Stock On Tuesday?Benzinga • 07/09/24
Indivior Cuts 2024 Outlook, Joins BP And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionBenzinga • 07/09/24
Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and CaPRNewsWire • 06/18/24
Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use DisorderPRNewsWire • 06/10/24
Opioid Use Disorder in the 7MM: Epidemiology Insights and Forecast 2024-2034 Featuring Detailed Analysis of Marketed and Late-Stage Pipeline Drugs, Including Subutex and INDV-2000 (Indivior)GlobeNewsWire • 06/05/24
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 GuidancePRNewsWire • 05/23/24
Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?Zacks Investment Research • 04/04/24
Indivior PLC (INDV) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 03/19/24
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal NaloxonePRNewsWire • 03/11/24
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict LitigationPRNewsWire • 02/29/24